Table 1:

Impact of disease modifying antirheumatic drugs on vaccine immunogenicity:

	Influenza	Pneumococcal	Herpes Zoster	Hepatitis B	Human papilloma virus	Tetanus	SARS-CoV-2 (mRNA)
Methotrexate	↓14,22,24	↓50,51	OK (ZVL)52		OK117,132,133	↓121	↓82,84,85
TNF-inhibitors	OK14,16,20,27,28	OK14,56	OK (ZVL) 64	↓103–105	OK 117,132	OK121,124*	OK 84,85,88
Rituximab	↓↓14–17,19–21,24,134	↓↓14,18,45–47				↓18,121	↓↓81,82–84
Abatacept	↓24,26	↓45,46				OK (SQ) 122 ↓(IV)123	↓84
JAK-inhibitor	OK30	↓30				OK (tofacitinib)120 ↓(baricitinib)53	↓82,84
IL-6R inhibitor	OK31	OK31				OK125	OK54
IL-12/23 inhibitor	OK32	OK54		↓105		OK84	OK 82
IL-17 inhibitor	OK33–35	OK55				OK55	OK84

OK: No significant/meaningful effect on vaccine immunogenicity (may include reduction in absolute post-vaccination titers if rates of protective titers are unchanged.) ↓: Reduces vaccine immunogenicity. ↓↓: Significantly reduces vaccine immunogenicity. For OK, ↓, and ↓↓: if no control group is available, data are compared to expected vaccine responses in the general population. Empty cells indicate a lack of data. TNF = tumor necrosis factor, JAK = Janus kinase, IL = interleukin, ZVL = zoster vaccine live, RZV = recombinant zoster vaccine, SQ = subcutaneous